Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Author(s)
Hartenian, E.; Shi, X.; Mikkelsen, T. S.; Heckl, D.; Ebert, B. L.; Root, D. E.; Doench, J. G.; Shalem, Ophir; Sanjana, Neville E; Scott, David Arthur; Zhang, Feng; ... Show more Show less
DownloadZhang_Genome-Scale.pdf (919.9Kb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
The simplicity of programming the CRISPR (clustered regularly interspaced short palindromic repeats)–associated nuclease Cas9 to modify specific genomic loci suggests a new way to interrogate gene function on a genome-wide scale. We show that lentiviral delivery of a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeting 18,080 genes with 64,751 unique guide sequences enables both negative and positive selection screening in human cells. First, we used the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, we screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic RAF inhibitor. Our highest-ranking candidates include previously validated genes NF1 and MED12, as well as novel hits NF2, CUL3, TADA2B, and TADA1. We observe a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, demonstrating the promise of genome-scale screening with Cas9.
Date issued
2014-01Department
McGovern Institute for Brain Research at MITJournal
Science
Publisher
American Association for the Advancement of Science (AAAS)
Citation
Shalem, O. "Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells." Science 343, 6166 (January 2014): 84-87 © 2014 American Association for the Advancement of Science (AAAS)
Version: Author's final manuscript
ISSN
0036-8075
1095-9203